Literature DB >> 26581986

Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins.

Sunil K Khattar1, Anthony L DeVico2, Celia C LaBranche3, Aruna Panda4, David C Montefiori3, Siba K Samal5.   

Abstract

Newcastle disease virus (NDV) expressing HIV-1 BaL gp160 was evaluated either alone or with monomeric BaL gp120 and BaL SOSIP gp140 protein in a prime-boost combination in guinea pigs to enhance envelope (Env)-specific humoral and mucosal immune responses. We showed that a regimen consisting of an NDV prime followed by a protein boost elicited stronger serum and mucosal Th-1-biased IgG responses and neutralizing antibody responses than NDV-only immunizations. Additionally, these responses were higher after the gp120 than after the SOSIP gp140 protein boost.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26581986      PMCID: PMC4719621          DOI: 10.1128/JVI.02847-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein.

Authors:  Rong Xu; Indresh K Srivastava; Catherine E Greer; Irina Zarkikh; Zane Kraft; Larene Kuller; John M Polo; Susan W Barnett; Leonidas Stamatatos
Journal:  AIDS Res Hum Retroviruses       Date:  2006-10       Impact factor: 2.205

2.  Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.

Authors:  Yuuei Shu; Sarah Winfrey; Zhi-Yong Yang; Ling Xu; Srinivas S Rao; Indresh Srivastava; Susan W Barnett; Gary J Nabel; John R Mascola
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

3.  Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.

Authors:  Y Li; K Svehla; N L Mathy; G Voss; J R Mascola; R Wyatt
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates.

Authors:  Alexander Bukreyev; Zhuhui Huang; Lijuan Yang; Subbiah Elankumaran; Marisa St Claire; Brian R Murphy; Siba K Samal; Peter L Collins
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

Authors:  Simon Beddows; Michael Franti; Antu K Dey; Marc Kirschner; Sai Prasad N Iyer; Danielle C Fisch; Thomas Ketas; Eloisa Yuste; Ronald C Desrosiers; Per Johan Klasse; Paul J Maddon; William C Olson; John P Moore
Journal:  Virology       Date:  2006-11-28       Impact factor: 3.616

6.  Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1.

Authors:  Antu K Dey; Kathryn B David; Per J Klasse; John P Moore
Journal:  Virology       Date:  2006-11-07       Impact factor: 3.616

7.  Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.

Authors:  Joshua M DiNapoli; Lijuan Yang; Amorsolo Suguitan; Subbiah Elankumaran; David W Dorward; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.

Authors:  Mattias N E Forsell; Yuxing Li; Maria Sundbäck; Krisha Svehla; Peter Liljeström; John R Mascola; Richard Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.

Authors:  E L Cooney; M J McElrath; L Corey; S L Hu; A C Collier; D Arditti; M Hoffman; R W Coombs; G E Smith; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

10.  Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.

Authors:  Joshua M DiNapoli; Alexander Kotelkin; Lijuan Yang; Subbiah Elankumaran; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

View more
  8 in total

1.  Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis.

Authors:  Ekaterina G Viktorova; Sunil K Khattar; Diana Kouiavskaia; Majid Laassri; Tatiana Zagorodnyaya; Eugenia Dragunsky; Siba Samal; Konstantin Chumakov; George A Belov
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

Review 2.  Mechanism of Viral Suppression among HIV Elite Controllers and Long-Term Nonprogressors in Nigeria and South Africa.

Authors:  Rahaman Ademolu Ahmed; Khalid Olajide Adekoya; Chika Kingsley Onwuamah; Bolanle Olufunmilayo Oboh; Smita Swaminathan Iyer; Ayomide Samuel Oluwatosin; Rosemary Ajuma Audu; Oliver Chukwujekwu Ezechi
Journal:  Viruses       Date:  2022-06-10       Impact factor: 5.818

Review 3.  Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use.

Authors:  Julia P C Fulber; Amine A Kamen
Journal:  Viruses       Date:  2022-05-06       Impact factor: 5.818

Review 4.  A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines.

Authors:  Ebony N Gary; Michele A Kutzler
Journal:  Clin Med Insights Pathol       Date:  2017-03-30

Review 5.  Avian Orthoavulavirus Type-1 as Vaccine Vector against Respiratory Viral Pathogens in Animal and Human.

Authors:  Julianne Vilela; Mohammed A Rohaim; Muhammad Munir
Journal:  Vaccines (Basel)       Date:  2022-02-08

Review 6.  Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines.

Authors:  Shin-Hee Kim; Siba K Samal
Journal:  Viruses       Date:  2016-07-04       Impact factor: 5.048

7.  Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus.

Authors:  Vinoth K Manoharan; Sunil K Khattar; Celia C LaBranche; David C Montefiori; Siba K Samal
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

Review 8.  Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV.

Authors:  Sarah Wilmschen; Joern E Schmitz; Janine Kimpel
Journal:  Vaccines (Basel)       Date:  2019-09-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.